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decreased to2 or fracture occurrence (“Delayed ZOL”). After 60months, Upfront
ZOL increased both BMD and disease-free survival (P.05) relative to Delayed ZOL.
The present analysis assessed the cost effectiveness of Upfront vs. Delayed ZOL in
this population, fromGerman (DE) and Italian (IT) payer perspectives.METHODS:A
Markov state-transition model was constructed to estimate the lifetime costs and
QALY for hypothetical cohorts of pmBCa women receiving Letrozole with Upfront
or Delayed ZOL. Consistent with ZO-FAST, at baseline, patients were 57 years old
and BCa-recurrence free. Patients could progress over time to “Local Recurrence”,
“Contralateral Tumor”, “Distant Recurrence”, or Death. Annual transition probabil-
ities were derived from ZO-FAST, supplemented with literature estimates. Direct
costs and utilitieswere literature-based. All resultswere discounted using country-
specific rates. RESULTS: In IT, Upfront ZOL treatment was associated with 15.01
QALYs and €21 998. Delayed ZOLwas associated with 13.98 QALYs and €19 458. Thus,
Upfront ZOL cost €2 453/QALY. In DE, Upfront ZOL treatment resulted in 15.44 QALYs
and €24 032. Delayed ZOL was associated with 14.37 QALYs and €23 081. Therefore,
Upfront ZOL cost €888/QALY. In both countries, the results were very insensitive to
changes in individual model input values. Compared to Delayed ZOL, Upfront ZOL
treatment cost€20000/QALY in95%of 1000probabilistic sensitivity analysismodel
runs in both IT and DE. CONCLUSIONS: This analysis suggests that treatment with
Upfront ZOLmay reduce recurrence and increase QALY and is highly cost effective
relative to a Delayed ZOL strategy from an IT and DE health care perspective.
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OBJECTIVES: Breast Cancer (BC) is the first cause of death among women, and it
progresses to metastatic breast cancer (MBC) in half of the cases. HER-2 overex-
pression is a marker of the worst prognosis and the target of guided therapies. The
aim of this study is to assess the cost-effectiveness of therapies against BC with
overexpressed HER-2 in Colombia. METHODS: A cost-effectiveness study of MBC
treatment in HER-2-positive patients progressing to Trastuzumab was conducted,
with a 5-year horizon. Lapatinib  Capecitabine was compared to Herceptin 
chemotherapy (Capecitabine, Vinorelbine or a Taxane). The effectiveness rates of
those therapies were identified based on published primary studies. In the absence
of head-to-head comparisons, Weibull functions for each chemotherapy were es-
timated from the survival curves and were multiplied by their hazard ratios. The
perspective was that of the third payer including all direct medical costs based on
Standard National Tariffs. Finally, a Markov model was developed, incremental
cost-effectiveness ratios, (ICER), sensitivity analysis, and acceptability curve were
estimated. The discount rate used was 3%. RESULTS: Lapatinib  Capecitabine
(LC) is the most effective and less expensive alternative. Hence, it overcomes the
alternatives. The cost-effectiveness ratio of such strategy is Col$49 725 045 per year
of life gained. CONCLUSIONS: The strategy with lapatinib is cost-effective in the
treatment of MBC after progression to Herceptin.
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COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND
TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH
EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER
Sura SD, Sansgiry SS
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OBJECTIVES: The objective of this study was to estimate the cost-effectiveness of
Aromatase Inhibitors (AIs) (anastrozole, letrozole and exemastane) and tamoxifen
as adjuvant treatment of postmenopausal women with hormone receptor positive
early breast cancer. METHODS: A Markov model comprising of five health states
(on treatment, local recurrence, distant cancer, die due to breast cancer and die due
to other causes) was developed to estimate the incremental cost per quality ad-
justed life-year (QALY) gained for anastrozole, letrozole, exemestane and tamox-
ifen. The analysis was carried out from a third party payer perspective. Transition
probabilitieswere estimated based on randomized clinical trials. Drug costs, health
utilities, and direct and indirect costs were obtained from published literature. The
timehorizonusedwas 25 years for the hypothetical cohort of 1000 postmenopausal
women with hormone receptor positive breast cancer. Costs and QALY were dis-
counted by 5% annually. Sensitivity analyseswere performed by varying the values
of key parameters, QALY and costs. RESULTS: Under base case assumptions, more
QALYs per patient would be gained with letrozole (4.6) than with anastrozole (3.6),
exemestane (3.6) and tamoxifen (3.3). The cost of gaining one QALY with letrozole
was $42,307 compared with exemestane ($71,081), tamoxifen ($76,826) and anas-
trozole ($ 78,114). The estimated ICER of letrozole, exemestane and anastrozole
compared with tamoxifen was -$47,560, $9,828 and $93,513 respectively. These
resultswere robust to the two-way sensitivity analyses performed.CONCLUSIONS:
In our analysis, letrozole was the cost-effective treatment compared to anastro-
zole, exemestane and tamoxifen for the primary adjuvant treatment postmeno-
pausal women with hormone receptor positive early-stage breast cancer. Instead
of comparing only monotherapy for cost-effectiveness, future research should
consider combination therapy while allowing switching between drugs.
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OBJECTIVES: To develop a cost-effectiveness analysis based on PFS of pazopanib
versus sunitinib in the treatment of aRCC in the Mexican context.METHODS: First
an adjusted indirect comparison was calculated between pazopanib versus inter-
feron (IFN) and pazopanib versus sunitinib. The hazard ratio (HR) of pazopanib
versus BSCwas obtained from the IRC subanalysis based on scan dates for patients
who progressed; same for sunitinib versus IFN. The HR of IFN versus BSC was
obtained from the MRCRCC study. A Markov model comparing pazopanib versus
sunitinib was designed with a two years time horizon and with a 5% discount in
costs and effectiveness. The costs of drugs and adverse events (AE) grades III and IV
were included for both alternatives.We did a probabilistic sensitivity analysis (PFS)
with 1,000 simulations. Exchange rate: 1USD  13.6MXN. RESULTS: The adjusted
indirect comparison yield a HR for pazopanib versus IFN of 0.545(95% CI, 0.341-
0.871) and for pazopanib vs. sunitinib of 1.012(95% CI, 0.613-1.670). The cost-effec-
tiveness analysis showed a reduction in average cost per patient of $8171 and a
reduction of 1.15 days PFSwhenusing pazopanib compared to sunitinib; incremen-
tal cost-effectiveness ratio (ICER) of $2,525,515 per PFS year (Mexican threshold is
$13,900). According to the PSA 0.7% cases were more effective at a higher cost,
47.4% cases were more effective at a lower cost and 51.9% cases were less effective
at a lower cost comparedwith sunitinib. TheAEs cost analysis showed that the cost
of treating AEs of sunitinib was $982(95% CI, $788-$1,112) and for pazopanib was
$137(95% CI, $87-$192). CONCLUSIONS: Based on PFS time pazopanib demon-
strated to be an equivalent alternative to sunitinib in the treatment of aRCC.
Sunitinib had an ICER considerably above the Mexican threshold. Pazopanib
showed a different toxicity profile that was considerably less costly compared to
sunitinib.
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HSCT is used as the treatment of hematologic malignancies and BuCy2 is a condi-
tioning regimen before HSCT but is associated to high rates of hepatic veno-occlu-
sive disease (HVOD) mainly due to busulfan (oralBu) plasma concentration vari-
ability after oral administration. Intravenous busulfan (IVBu) shows constant
plasma concentration allowing better targeting of plasma exposure and reducing
occurrence of HVOD. OBJECTIVES: Develop an economic model based in Mexican
Institute of Social Security (IMSS) resource payments to evaluate the cost-effective-
ness of oralBu versus IVBu as conditioning regimen before HSCT in Mexico.
METHODS: A two branch decision tree model in patients with 40 or 60 kg of weight
was developed to evaluate the cost-effectiveness in Mexican pesos (MxP) of IVBu
(0.8mg/Kg/6hrs) or OralBu (1mg/Kg/6hrs) combined with intravenous cyclophos-
phamide (60mg/kg/tid) as conditioning regimen before HSCT. The effectiveness
measure was HVOD non-occurrence obtained from published clinical trials. Re-
source use and costwere obtained froman expert panel survey and IMSS published
data. The model estimated non discounted cost per patient and incremental cost-
effectiveness ratios. Probabilistic sensitivity analysis was performed using Monte
Carlo simulation second-order approach and deterministic analysis. RESULTS:
HVOD non-occurrence was 84.88% in IVBu group and 51.34% in oralBu group. Cost
per patient was lower with IVBu ($148,712.19 - $180,562.79 MxP) than OralBu
($291,088.60 to $293,296.88 MxP) showing that IVBu was the dominant alternative.
Sensitivity analysis showed model robustness and confirm IVBu as dominant.
CONCLUSIONS: IVBu is a cost-effective conditioning regimen inMexico and should
be considered by clinicians and decision makers as a favorable option before Allo-
geneic HSCT.
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OBJECTIVES: To evaluate cost-effectiveness of abiraterone and cabazitaxel com-
pared to existing palliative chemotherapy, mitoxantrone and placebo for meta-
static castration-resistant prostate cancer (mCRPC) patients; focusing on differ-
ences in baseline illness severity. METHODS: A decision tree comparing four
treatment strategies in mCRPC patients over an 18-month-period was constructed
from the societal perspective. Chance nodes included baseline pain as a severity
indicator, grade III & IV neutropenia or cardiac events, and survival at 18 months.
Probabilities and life expectancies were from two clinical trials (COU-AA1 and
TROPIC2). Costs in 2010 US dollars included drugs (Redbook), physician visits, pro-
cedures, tests (CPT-codes) and hospitalizations (HCUP). Model cost inputs included
drugs, chemotherapy administration, adverse events management, radiotherapy
for pain palliation, and death. The short duration excluded need for discounting.
Utilities for bone pain, neutropenia, cardiac events and radiation therapy were
from published sources. Baseline severity was altered to reflect relatively ill
populations. RESULTS: Cabazitaxel and abiraterone give the best effects and caba-
zitaxel ismost costly. Formitoxantrone as comparedwith placebo, the incremental
cost effectiveness ratio (ICER) was $110K/QALYS and $63K/LYS. For abiraterone
versus mitoxantrone, the ICER was $76K/QALYS and $52K/LYS. Cabazitaxel has an
ICER of $925K/QALYS and $378K/LYS compared to abiraterone. One-way and prob-
abilistic sensitivity analyses show a robust model for most variables. This re-
mained so across the majority of WTP thresholds shown in acceptability curves
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and net monetary benefit calculations. Sensitive variables include abiraterone
costs and neutropenia costs of mitozantrone. Even assuming most patients are
severely ill to match sites with sicker populations, the relative cost-effectiveness
does not change; abiraterone favored and cabazitaxel always above tolerable
thresholds. CONCLUSIONS: Abiraterone is the most cost effective given WTP of
$100,000. Despite slightly higher survival with cabazitaxel, it is never cost-effective
with high drug andneutropenia costs. Even for care siteswith relatively ill patients,
abiraterone remains cost-effective.
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OBJECTIVES: Cancer is a risk factor to develop deep vein thrombosis (DVT), pulmo-
nary embolism (PE) or relapse of these conditions. Alternatives to oral anticoagu-
lants need to be evaluated. The objective of this study was to perform an economic
evaluation of anticoagulant therapies in adult patients with cancer (solid tumors),
from the Social SecurityMexican Institute (IMSS) perspective.METHODS:One-year
medical direct costs (2011 US$) and health consequences were estimated by a
Markov model (one-week cycles). Effectiveness measures were reduction in cases
of DVT and PE (per 1000 patients). A meta-analysis was performed to estimate
transition probabilities. Alternatives considered in the assessment were: warfarin
(5mg/day); dalteparin (not listed in Mexican formulary, 5000 IU/day); enoxaparin
(40 mg/day); nadroparin (5700 IU/day); unfractionated heparin (UFH) plus warfarin
(10000 IU/day5 mg/day) and no prophylaxis. Resource use and costs were ob-
tained through IMSS databases (dalteparin acquisition cost was provided by man-
ufacturer). Univariate sensitivity analysis was performed. Acceptability curves
were constructed. RESULTS: Estimated cases of DVT avoidedwere: warfarin 276 (CI
95% 271–281); dalteparin 47 (46–48); enoxaparin 107 (105–109); nadroparin 97 (95–
99); UFH 127 (124–130) and no prophylaxis 317 (310–323). Regarding PE prevention,
outcomes were: warfarin 116 (114–118); dalteparin 16 (16–16); enoxaparin 23 (23–
23); nadroparin 15 (15–15); UFH 26 (25–27) andno prophylaxis 61 (60– 62). Per patient
annual costs were: warfarin $1908.32 ($1851.38-$1918.42); dalteparin $2298.82
($2268.41-$2329.22); enoxaparin $3713.36 ($3634.27-$3792.46); nadroparin $2,648.14
($2603.54-$2692.76); UFH $1884.90 ($1851.38-$1918.42) and no prophylaxis $2667.81
($2619.18-$2716.42). For both DVT and PE, ICER=s of dalteparin, enoxaparin and
nadroparin were $1.72, $3.93; $10.70, $19.44, $4.15 and $7.35, respectively. In pre-
vention of bothDVTand PE, dalteparin ismore effective and less costly than enoxa-
parin, nadroparin and no prophylaxis. CONCLUSIONS: Dalteparin is a potential
cost-effective antithrombotic therapy in adult patients with cancer in Mexico.
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OBJECTIVES: To evaluate the cost-effectiveness of Everolimus as second-line of
treatment compared with sorafenib in adult patients with metastatic renal cell
carcinoma, from the perspective of the Mexican Public Health Institution.
METHODS:We compare the results obtained in treating renal cancer patients with
either sorafenib or everolimus, previously treated with sunitinib in Mexico. We
developed amarkovmodel in a two-year period among three possible health states
(stable, progression and death). Overall survival and progression-free survivalwere
used as effectivenessmeasures and the sources of this informationwere published
articles. We considered the costs of drugs, best-supportive care and follow-up
(stable disease and progression); drug costs of everolimus and sorafenib only apply
to stable patients. The costs of medical resources correspond to the costs of med-
ical care in tertiary care systems. All costs were calculated in 2010 Mexican pesos.
An incremental analysis of cost and results in health was realized, to compare
everolimus and sorafenib. A sensitivity analysis was also accomplished (determin-
istic and probabilistic). The discount rate applied to costs and effectivenesswas 5%.
RESULTS: Patients with everolimus obtained more overall survival (14.37 vs. 7.73
months) and progression-free survival (4.83 vs. 3.88 months) than those that used
sorafenib. Everolimus resulted as the alternative with less average total cost than
sorafenib: $391,765.00 and $454,802.00 respectively. Everolimus is a dominant op-
tion compared with sorafenib. Sensitivity analysis showed robustness in the
results. CONCLUSIONS: Everolimus is the cheapest treatment option and saving of
resources, which significantly increases the survival of patients and provides lon-
ger progression-free and more overall survival versus sorafenib.
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OBJECTIVES:To evaluatewhether the use of bevacizumab in first line treatment for
patients with advanced ovarian cancer represents a cost-effective strategy for
health institutions in Mexico. METHODS: Ovarian Cancer is the sixth most com-
mon cancer and second gynecologic malignancy worldwide, with approximately
190,000 new cases per year. Ovarian cancer is considered highly lethal for their
growth characteristics, low symptoms and recurrence. A complete economic eval-
uation of cost-effectiveness was performed in womenwith ovarian cancer stage III
and IV, classified as high risk, taking carboplatin  paclitaxel (CP) and bevaci-
zumab carboplatinpaclitaxel (BCP) as comparators. The 1st cycle, carboplatin
paclitaxel are administered alone; from 2nd to 6th is added bevacizumab
(7.5 mg/kg). From cycle 7, all patients with no evidence of disease progression
received maintenance bevacizumab as monotherapy, giving a maximum of 18
cycles. The progression was emulated with aMarkovmodel considering the stages
of: progression free survival, progression and death in a 11.5 year time horizon.
Costs are expressed in US dollars. RESULTS: BCP gained more months with pro-
gression free survival compared with CP (16.77 vs. 14.40). BCP obtained 40.89
months of overall survival versus 31.17 with CP, generating a 36% increase in over-
all life expectancy. The Incremental Cost Effectiveness Ratio (ICER) for BCP is
$25,544 per year of additional life year gained with respect the use of CP. According
to the International Monetary Fund, the Gross Domestic Product (GDP) for Mexico
in 2011 was $9471. For a threshold of 3 times this value (3 GDP per capita: $28,413),
the use of BCP in advanced ovarian cancer would be cost-effective. CONCLUSIONS:
BCP is an alternative that substantially increases the patient overall survival ex-
pectancy. It also lies within the international cost-effectiveness threshold.
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OBJECTIVES:Assesswhether the use of Erlotinib as 1st line treatment inmetastatic
or advanced Non Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth
Factor Receptor (EGFR) mutation positive, is a dominant alternative from the per-
spective of public health system in Mexico. METHODS: It was developed a cost-
utility analysis using a Markov model with monthly cycles stages: response to
treatment, stable disease, disease progression and death in a time horizon of 5
years. The costing method is the direct medical costs and the main outcome mea-
sures were QALY’s and total cost of treatment per patient. The drugs compared in
the study were Erlotinib, Gefitinib and chemotherapy with Gemcitabine plus Car-
boplatin. Costs are expressed in US dollars. RESULTS: Erlotinib was the alternative
that provided a greater number of QALY’s (1.49) compared with Gefitinib (1.32) and
chemotherapy with Carboplatin (1.07). Furthermore, treatment with Erlotinib was
the least expensive with a cost per patient of $51,249 on a horizon of 5 years while
the cost of Gefitinib was $ 53,817 per patient and the QT with Gemcitabine 
Carboplatin $53,258 per patient. This implies that the dominant treatment for
these patients (NSCLC and positive EGFR mutation) is Erlotinib with a cost-effec-
tiveness average of $34,456. The dominance results of treatment with Erlotinib
were consistent with sensitivity analysis, which provides robustness to the results.
CONCLUSIONS: Considering the average annual costs, Erlotinib represents savings
for the health sector from $402 (versus Gemcitabine  Carboplatin) to $514 (vs
Gefitinib) for each patient according to its comparator in 1 year. Therefore, under
the context of public health system inMexico, treatment with Erlotinib was shown
to be a cost-effective treatment and dominant over other treatment alternatives
considered in this study for patients with NSCLC and EGFR mutation.
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OBJECTIVES: The aim of this study is to assess efficiency of adding rituximab to
fludarabine and cyclophosphamide (R-FC versus FC) for the treatment of previ-
ously untreated chronic lymphocytic leukemia in Ukraine. METHODS: A cost-ef-
fectiveness analysis was performed from a health care perspective over a 20 year
horizon with 3% discounting rate. Markov model in Excel program (2007) with
cohort simulation was applied. Three-state model (no disease progress, relapse,
and death) was run using one month cycle time. The outcome data were retrieved
from a randomized controlled trial publication. One-way sensitivity analysis was
performed to assess robustness of the results. RESULTS: The incremental life ex-
pectancy increase was 3.27 months on R-FC in comparison to FC scheme. The
expected costs associated with FC scheme are equal to $28,105 and with FC-R
scheme to $41,850. R-FC was associated with incremental 1.3 quality-adjusted life-
years (QALYs) compared to FC and resulted in an incremental cost-effectiveness
ratio of $10,588 per QALY from health care perspective. Results were themost sensi-
tive tounitdrugcost for rituximab (costsdeviation$1.77-3.88permg).CONCLUSIONS:
The World Health Organization recommends to consider drugs cost-effective if their
incremental cost per QALY is less than 3 gross domestic product per capita in the
country ($6,700/per capita inUkraine). Under these recommendations, R-FC scheme is
seen as cost-effective in Ukrainian health-care setting.
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THE COST-EFFECTIVENESS OF TEMOZOLOMIDE IN THE ADJUVANT
TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA IN THE UNITED STATES
Messali A, Hay J, Villacorta R
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The objective of this researchwas to determine the incremental cost-
effectiveness, from a US societal perspective, of adding temozolomide to the pre-
vious standard of care (radiotherapy only) for the adjuvant treatment of newly
diagnosed glioblastoma. METHODS: A Markov model with a one-month cycle
length and five-year time horizon was constructed in Microsoft Excel. All model
parameters were obtained from relevant peer-reviewed literature based on sys-
tematic review. Transition probabilities were calculated using survival data from
randomized controlled trials comparing temozolomide plus radiotherapy versus
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